Phase 4 N=19 European New Texture Implant Clinical Experience With Shaped Breast Implants
Breast Augmentation
Primary: Investigator Overall Satisfaction With the Device Using a 5-Point Scale — 4.6 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=14 Depression-Diabetes Mechanisms: Urban African Americans
Diabetes · Depression
Primary: Response of Participants, Defined by Change in the 21-item Hamilton Depression Rating Scale (HDRS) From Baseline to Week 24 — 2; 1; 2; 1 participants
Phase 4 N=114 A Study of Tarceva (Erlotinib) in Elderly Patients With Advanced Non-Small Cell Lung Cancer
Non-Small Cell Lung Cancer
Primary: Percentage of Participants Achieving a Best Overall Response of Complete Response (CR) or Partial Response (PR) — 22.81; 8.93 percentage of participants — p=0.0388
Phase 4 N=10 Tolvaptan for Ascites in Cirrhotic Patients
Ascites · Cirrhosis
Primary: Number of Participants With Worsening Ascites (Increase in Number of Paracentesis Procedures to Remove 2 Liters of Ascites Fluid) — 0 participants
Phase 4 N=80 Antiepileptic Drugs and Osteoporotic Prevention Trial
Epilepsy · Bone Loss · Osteoporosis
Primary: Changes in Bone Mineral Density — 1.025; 0.999; 1.332; 1.245 g/cm2
Phase 4 N=30 A Study of The Relationship Between Drop in Hemoglobin and Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Copegus (Ribavirin) and Pegasys (Peginterferon Alfa-2a)
Hepatitis C, Chronic
Primary: Percentage of Participants With Sustained Virological Response (SVR) 24 Weeks After End of Treatment — 83.3 percentage of participants — p=0.8333
Phase 4 N=70 Comparison of Pantoprazole and Ranitidine in Dyspepsia
Dyspepsia
Primary: Visual Analogue Scale Score — 39.6; 42.3; 27.6; 28.3 Visual Analogue Scale
Phase 4 N=224 IV Dexketoprofen vs Placebo in Migranie Attack
Migraine
Primary: Visual Analogue Scale Change — 55; 30 units on a scale
Phase 4 N=40 Depression, Epinephrine, and Platelet Function
Major Depressive Disorder
Primary: Response of Participants, Defined by Change in the 21-item Hamilton Depression Rating Scale (HDRS) From Baseline to Week8 — 5; 9; 2; 4 participants — p=.918
Phase 4 N=15 Intranasal Midazolam in Children as a Pre-Operative Sedative
Sedation, Conscious
Primary: Sedation Scale Score — 0; 0; 0; 1 participants — p=0.99
Phase 4 N=356 A Study Comparing Monthly Boniva (Ibandronate) and Weekly Risedronate in Women With Post-Menopausal Osteoporosis.
Post Menopausal Osteoporosis
Primary: Percentage of Participants Who Preferred Ibandronate Monthly Dosing to Risedronate Weekly Dosing — 81.7; 78.2; 79.9 percentage of participants — p=<0.0001
Phase 4 N=19 The Effects of Milnacipran on Sleep Disturbance in Fibromyalgia
Sleep Disorders · Fibromyalgia · Sleep
Primary: Number of Awakenings After Sleep Onset (NAASO) — 39.5; 34.9 Awakenings — p=0.424
Phase 4 N=16 Pathophysiology of Post Amputation Pain
Amputation Stumps · Neuroma
Primary: Change in Pain — -0.3; -2; -1; 1.3 units on a scale
Phase 4 N=32 Investigation of Intraocular Pressure (IOP) Reduction Efficacy of Travoprost Ophthalmic Solution in Patients With Normal Tension Glaucoma
Normal Tension Glaucoma · Ocular Hypertension
Primary: Mean Change From Baseline in IOP (9:00 AM) at Week 4, Week 8, and Week 12 — 16.55; -3.37 mmHg
Phase 4 N=79 Investigate the Impact of Early Treatment Initiation With Tiotropium in Patients Recovering From Hospitalization for an Acute COPD Exacerbation 2
Pulmonary Disease, Chronic Obstructive
Primary: Change From Baseline of Trough FEV1 at 12 Weeks on Study Drug. — 0.124; 0.186 Litres